Skip to main content
Clinical Trials/KCT0005545
KCT0005545
Recruiting
未知

Bone-guided regeneration of NR Line implant peripheral defects: a prospective randomized clinical study

Yonsei University Health System, Dental Hospital0 sites40 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Diseases of the musculo-skeletal system and connective tissue
Sponsor
Yonsei University Health System, Dental Hospital
Enrollment
40
Status
Recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Observational Study
Sex
All

Investigators

Sponsor
Yonsei University Health System, Dental Hospital

Eligibility Criteria

Inclusion Criteria

  • 1\) Over 20 years old
  • 2\) Implant placement does not have any contraindicated systemic/localized disease or condition
  • 3\) In the maxilla or mandible, a deterioration defect of 3 mm or more in apex\-crown width should be expected to occur around at least one implant.
  • 4\) The initial stability of the implant is secured
  • 5\) Implant placement should be done at least 2 months after extraction
  • 6\) No soft tissue transplantation required after implant placement
  • 7\) Implant placement should be done at least 2 months after soft tissue transplantation.
  • 8\) Non\-smokers, smokers who smoke less than 10 cigarettes a day
  • 9\) Those with no possibility of pregnancy

Exclusion Criteria

  • 1\) Those who have taken medicines that interfere with bone formation within 2 weeks from the time of screening (e.g., adrenal corticosteroids) or are likely to take them during the clinical trial period
  • 2\) Those who administered oral or injectable rheumatism treatment including immunosuppressants within 2 weeks from the time of screening
  • 3\) Patients with uncontrolled diabetes or high blood pressure
  • 4\) Those with oral skin diseases or lesions (eg, erosive lichen planus, erosive lichen planus, stomatitis, ulcers, malignant tumors)
  • 5\) Those suffering from osteomyelitis
  • 6\) In the past, oral or injectable bisphosphonate drugs to treat osteoporosis for more than 3 months
  • Those who have been or are receiving the administration (However, according to the AAOMS standard, discontinuation of the administration for more than 3 months, those with a CTx level of 0\.150ng/ml or more may participate in the clinical study)
  • 7\) A person who meets any of the following items in the area where the test/control medical device is applied
  • i. Those with past bone graft or implant experience
  • ii. Those who have had a tumor removed in the past

Outcomes

Primary Outcomes

Not specified

Similar Trials